

Blood Group Genotyping in Germany

**FDA, Workshop on Molecular Methods in
Immunohematology**

**Lister Hill Auditorium, NIH Bldg 38A
Bethesda 25 – 26 Sept 2006**


Willy A. Flegel MD

Professor of Transfusion Medicine

Institut Transfusionsmedizin, Universitätsklinikum Ulm
Institut für Klinische Transfusionsmedizin und
Immungenetik Ulm gGmbH (IKT Ulm)

Clinical management of D antigen in Germany

- two anti-D monoclonals
 - that do not bind DVI
 - German guidelines since 1996
- RhIg
 - prenatal & post partum
- CcEe antigens, if
 - girl
 - woman < 45 years
 - multiple transfusions
 - immunhematologic problems
- D antigen most immunogenic
 - because RhD protein is completely lacking in D neg.
- most important blood group system encoded by proteins




Clinical applications

- Patients with weak D phenotypes
 - prevalent weak D should be transfused D pos.
- Maternal care
- Blood donors
- Anti D and family planning


Distribution of molecular *weak D* types in Europeans

- weak D type 1 to 4: 94%
- less frequent weak D types combined: 6%
- often confirmed in Europeans
- details vary among European populations
- e.g. Portuguese: weak D type 2 most frequent
 - Blood 93(1999)385



weak D types among transfusion recipients with anti-D

- 31 observations since 1998
- prevalent weak D: auto-anti-D only n=24
- weak D type 4.0 n=3, low titer
- allo-anti-D * n=4
 - weak D type 4.2, 11 & 15
 - Blood 95(2000)2699 <http://www.uni-ulm.de/~wflegel/RH/RIR/#title>



Clinical management of patients with a weak D phenotype

Table 1 Weak D types that are prevalent or clinically relevant in Europeans

Weak D phenotype	Prevalence in Germany	Haplotype association	Transfusion recipients with anti-D (n)*			Recommended management		Clinical consequences
			Total	Allo- anti-D	Auto- anti-D	RBC unit transfusion	RhIg in pregnancy?	
Type 1	0.2964%	CDe	15	0	15	D-pos.	No	Established
Type 2	0.0759%	cDE	8	0	8	D-pos.	No	Established
Type 3	0.0219%	CDe	0	n.a.	n.a.	D-pos.	No	Established
Type 4.0	0.014%	cDe	3	See remark	See remark	D-pos.	No	Pending
Type 4.1	0.023%	cDe	0	n.a.	n.a.	D-pos.	No	Established
Type 4.2	Rare	cDe	2	1	1	D-neg.	Yes	Established
Type 5	0.0035%	cDE	1	0	1	D-neg.	Yes	Pending
Type 11	>0.0009%, 0.0009%	CDe, cDe	1	1	0	D-neg.	Yes	Established
Type 15	Rare	cDE	1	1	0	D-neg.	Yes	Established
Type 19	0.067%	CDe	0	n.a.	n.a.	D-neg.	Yes	Pending
Type 20	0.024%	cDE	0	n.a.	n.a.	D-neg.	Yes	Pending
Other types	Rare	Variable	0	n.a.	n.a.	D-neg.	Yes	Pending

– Flegel WA: Curr Opin Hematol 2006 in press

Patient testing for clinically relevant weak D types

- may save 3% – 5% of all D neg. units for D neg. recipients who really need them
- one test per patient
- CE-labelled test kits
- offered as a service in Germany since 2000
- protocol details published in e.g.
 - Flegel WA
Curr Opin Hematol 2006 in press

Clinical applications


- Patients with weak D phenotypes
- Maternal care
 - prenatal diagnostics
 - RhIg in pregnancy
- Blood donors
- Anti D and family planning

Prenatal diagnostics

- blood group genotyping is standard care
 - puncture of fetal cord contra-indicated, if done for blood group typing only
 - German consensus statement
Infusionsther Transfusionsmed 27(2000)215
- typical diagnostic requests in Germany
 - from amniotic fluid or its cell culture
 - in order of frequency:
 - D
 - Rhesus phenotype (CcEe)
 - K
 - Fy, Jk etc. (sporadic requests only)
- fetal *RHD* from maternal plasma
 - not widely available in Germany at this time

Rhlg during pregnancy may be dropped, ...

- ... if mother carries certain weak D types
- ... if fetus types D neg. from maternal plasma



- Blood 93(1999)385
- Curr Opin Hematol 2006 in press

Noninvasive Prenatal Diagnosis of Fetal Rhesus D

Ready for Prime(r) Time

Diana W. Bianchi, MD, Neil D. Avent, PhD, Jean-Marc Costa, PhD, and C. Ellen van der Schoot, MD, PhD

- Obstet Gynecol 106(2005)841

Health and cost benefits

Rhlg may be dropped, ...

- ... if mother carries certain weak D types
 - may save 3% – 5% of all anti-D shots
 - one test per mother's lifetime
 - test pays for itself
 - health benefit for mother may come for free
- ... if fetus types D neg. from maternal plasma
 - may save 40% of prenatal anti-D shots
 - one or more tests per pregnancy
 - test may pay for itself

Regulatory issues

Rhlg may be dropped, ...

- ... if mother carries certain weak D types
- ... if fetus types D neg. from maternal plasma
- CE-labelled test kits
- no test kit available
- compatible with current guidelines
- guidelines would need to be relaxed
- offered as a service in Germany since 2001
- currently not offered as a service in Germany

Clinical applications

- Patients with weak D phenotypes
- Maternal care
- Blood donors
 - screen for DEL, weak D and D⁺/D⁻ chimera among serologically D neg. donors
- Anti D and family planning

Rationale: to improve RBC unit safety

- potential immunogenicity of weak D, DEL and D⁺/D⁻ chimera
- *RHD* with very weak D antigen expression
 - detectable by adsorption/elution or flow cytometry
 - it should be remembered: there are *RHD* alleles without any serologically detectable D antigen
 - Transfusion 45(2005)1547

Routine testing 1/02 – 12/05 at our blood service


- testing of all first time donors for D antigen
 - serology according to German guidelines
 - oligoclonal anti D plus antiglobulin test in gel technique
- screening of all serologically D negative first time donors for *RHD* gene
 - 29,823 in 4 years
- PCR screening of pools of 20 donors
 - PCR-SSP for *RHD* intron 4
- all novel *RHD* alleles characterized
 - PCR, sequencing, testing for DEL

Distribution among Rhesus phenotypes

Phenotype	N	<i>RHD</i> positive	DEL positive
Ccddee	27,859	8	0
Ccddee	1,241	44	23
ccddEe	679	7	1
CCddee	20	2	2
CcddEe	19	0	0
ccddEE	4	0	0
CCddEe	1	0	0
total	29,823	61	26

Frequency distribution

■ frequency among D neg. donors



RHD alleles expressing DEL differ among ethnic groups

Population	Prevalence in D-negative blood donors		Prevalent <i>RHD</i> alleles
	Any <i>RHD</i> allele	DEL phenotype	
Europeans	0.2%	1 in 1000	<u><i>RHD</i>(IVS3+1G>A),</u> <u><i>RHD</i>-CE(8-9)-D,</u> <u><i>RHD</i>Ψ, weak</u> <u><i>D</i> type 11 in CDe*</u>
Africans	10%	<1 in 100	<i>RHD</i> Ψ, Cde ^s
East Asians	30%	1 in 3	<u><i>RHD</i>(K409K),</u> <u>weak <i>D</i> type 15,</u> <u>weak <i>D</i> type 17</u>

– Flegel WA: Curr Opin Hematol 2006 in press

***RHD* genotyping in donors: improves RBC unit safety**


- by moving donors with
 - weak D, DEL & D⁺/D⁻ chimeric RBC populations
- to the D positive donor pool
- obviates need for very sensitive anti-D test and its quality assurance (cost savings)
- adaptation to allele distributions in different populations required
 - protocols for e.g. East Asia
Transfusion 45(2005)345 and in press

Clinical applications

- Patients with weak D phenotypes
- Maternal care
- Blood donors
- Anti D and family planning
 - genotype father for *RHD* heterozygosity, if mother carries anti D

Detection of *RHD* heterozygous status in fathers

- hybrid *Rhesus box*



- Problem
 - *Rhesus box* variants
- Blood 95(2000)3665

- *RHD*/*RHCE* dosage





Fig. 3. Analysis of ccDee samples with large D antigen density by quantitative PCR.


- Problem
 - *RHCE-D-CE* alleles, like *D--*
- Transfusion 46(2006)1343

PCR-SSP for *RHD* deletion




- detection of *RHD* heterozygosity in a father

RHD genotyping




DD

homozygous



Dd

heterozygous



dd

Regulatory and liability issues

RHD heterozygous status

- hybrid *Rhesus box*
 - PCR with sequence specific primers (PCR-SSP)
 - Problem
 - *Rhesus box* variants primarily in Africans
 - Resolution
 - *RHD/RHCE* dosage by quantitative PCR
- best would be both tests, but one test is better than none*
- CE-labelled test kits
 - offered as a service in Germany since 2001
-
- Blood 95(2000)3665
 - Transfusion 45(2005)327&338
- *RHD/RHCE* dosage
 - quantitative real time PCR
 - Problem
 - *RHCE-D-CE* alleles, like *D--* primarily in Europeans (?)
 - Resolution
 - hybrid *Rhesus box* by PCR-SSP
- no test kit available
 - offered as a service in Germany (not in Ulm)
-
- Transfusion 46(2006)1343

Summary

Clinical applications in Germany

- Patients with weak D phenotypes
 - prevalent weak D should be transfused D pos.
- Maternal care
 - prenatal diagnostics
 - RhIg in pregnancy
- Blood donors
 - screen for DEL, weak D and D⁺/D⁻ chimera among serologically D neg. donors
- Anti D and family planning
 - genotype father for *RHD* heterozygosity, if mother carries anti D
- Next step forward
 - mass scale genotyping, e.g. biochips

Supplementary material

Editorials 2005

- Transfusion 45 (Mar 2005) 293

characterized and thus detected. Recently in Germany, PCR-based quality control of 15,045 serologically defined D- units revealed that 39 of them carried *RHD* alleles.¹⁰

- Transfusion 45 (Apr 2005) 466

many, *RHD* genotyping of D- first-time donors (among 500,000 donations/year) has been a routine procedure

- Transfusion 45 (Oct 2005) 1547


Since 2000, Flegel⁵ has tested all his D- donors in Ulm, Germany, by a molecular method to ensure detection of all forms of *RHD*.

Anti D immunization by “D neg.” blood donors

- weak D type 2
 - 1 immunization
 - Transfusion 40(2000)428
- D+/- chimera
 - > 2 immunizations
 - BMC Genet 2(2001)10
- weak D type 26
 - 1 immunization in pregnancy
 - Transfusion 45(2005)527
 - Editorial in Transfusion 45(2005)466
- DEL phenotype
 - *RHD*(IVS5-38del4)
 - 1 immunization
 - Transfusion 45(2005)520
- *RHD*(K409K)
 - most prevalent DEL type worldwide
 - 1 secondary immunization
 - Transfusion 45(2005)1581


Superior sensitivity: mistyped by routine serology

- missed among 8,442 “D neg.” donors
 - 3 partial D
 - 1 weak D type 2
 - 1 D+/- chimera
- D+/- chimera → total of 13 donations
 - caused anti-D in the latest 2 eligible transfusions
- it may be wise to revisit older serologic results




- BMC Genet 2(2001)10

Frequency distribution




Novel alleles per year



RH blood group system

RhD and RhCE proteins



● RhD vs. RhCE (yellow)

- C/c (green)
- E/e (black)

● weak D

- (red/orange)

● partial D

- (blue/light blue)

Type of D variant correlates with type of molecular variant

	Type of variant
D antigen	Allele (molecular type)
D category	<i>RHD-CE-D</i> hybrid alleles
partial D: European	exofacial single missense
partial D: African	exofacial dispersed missense
weak D	non exofacial single missense
DEL	e. g. splice site mutation
D negative	<i>RHD</i> deletion non functional rearranged non functional nonsense